Hot Pursuit     17-May-21
Rossari Biotech Q4 PAT rises 47% YoY to Rs 22 cr
Rossari Biotech reported a 47.1% jump in consolidated net profit to Rs 22.2 crore on a 36.8% rise in net sales to Rs 218.22 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, profit before tax jumped 46.3% to Rs 29.91 crore in Q4 FY21 as against Rs 20.44 crore registered in Q4 FY20.

During the quarter, the company successfully commissioned all phases of its greenfield manufacturing facility at Dahej, Gujarat. The unit has a total installed capacity 132,500 MTPA, enhancing the total capacity of Rossari by 2.1 times to 252,500 MTPA. The company expects to sustainably ramp-up utilization levels at the Dahej unit over the next 3-4 years.

EBITDA jumped 46.7% year on year to Rs 35.2 crore in Q4 FY21 from Rs 24 crore posted in the same quarter last year. EBITDA margins improved to 16.1% in Q4 FY21 from 15.1% in Q4 FY20.

The speciality chemical company posted a 22.7% rise in net profit to Rs 80 crore for the year ended March 2021 (FY21) from Rs 65.2 crore registered in the year ended March 2020 (FY20). Revenue from operations jumped 18.2% year on year to Rs 709.3 crore in FY21 from Rs 600 crore in FY20.

Commenting on the performance, in a joint statement, Edward Menezes, promoter & executive chairman, and Sunil Chari, promoter & managing director said, "Growth was primarily driven by a robust and continued uptick in sales in the HPPC segment led by higher offtake in hygiene products and antiviral portfolio sales. In addition, normalization in demand and improved consumption across the TSC and AHN business lines assisted overall results. Even on a full year basis, our performance, despite the unprecedented environment, has been resilient and we have ended FY2021 on a strong note, with revenues higher by 18.2% YoY and PAT higher by 22.7% YoY. In one of the key developments during the quarter, we have fully operationalized our state-of-the-art Greenfield manufacturing facility at Dahej. We have seen a strong ramp-up in utilization levels from this facility in recent months, leading to healthy volumes particularly in the HPPC segment. Going forward, a strong upcoming pipeline of new product launches should enable us to sustainably ramp-up utilization levels at this unit over the next 3-4 years. In the quarter gone by, we had seen normalization in demand and consumption sentiments across all the three business segments. Overall, we are confident that the stabilization of the demand environment and improved consumption will lead to stronger and sustainable growth in the quarters ahead."

Rossari Biotech is a speciality-chemicals manufacturer providing intelligent and sustainable solutions for customers across industries.

Shares of Rossari Biotech were down 3.24% at Rs 1246 on BSE.

Previous News
  Rossari Biotech consolidated net profit rises 17.77% in the March 2024 quarter
 ( Results - Announcements 30-Apr-24   07:29 )
  Board of Rossari Biotech approves incorporation of subsidiary in Dubai
 ( Corporate News - 06-Apr-24   17:38 )
  Rossari Biotech consolidated net profit rises 58.30% in the June 2021 quarter
 ( Results - Announcements 30-Jul-21   18:34 )
  Rossari Biotech to discuss results
 ( Corporate News - 24-Apr-23   10:13 )
  Rossari Biotech consolidated net profit rises 1.88% in the June 2023 quarter
 ( Results - Announcements 29-Jul-23   15:26 )
  Board of Rossari Biotech recommends Final Dividend
 ( Corporate News - 21-May-22   12:13 )
  Board of Rossari Biotech approves preferential issue of shares up to Rs 300 cr
 ( Corporate News - 24-Mar-21   09:28 )
  Volumes spurt at Rossari Biotech Ltd counter
 ( Hot Pursuit - 12-Oct-22   11:00 )
  Board of Rossari Biotech approved acquisition of 50.10% stake in Romakk Chemicals
 ( Corporate News - 31-Jul-21   12:08 )
  Rossari Biotech announces cessation of director
 ( Corporate News - 04-Jul-23   12:27 )
  Rossari Biotech consolidated net profit rises 4.35% in the December 2021 quarter
 ( Results - Announcements 15-Feb-22   08:24 )
Other Stories
  Patanjali Foods Q4 PAT slides 21% YoY to Rs 206 cr
  15-May-24   16:10
  Jyothy Labs Q4 PAT rises 32% YoY to Rs 78 cr
  15-May-24   15:29
  Aarti Pharmalabs Ltd leads losers in 'A' group
  15-May-24   15:00
  PFC spurts as Q4 PAT jumps 20% YoY to Rs 5,624 cr
  15-May-24   14:58
  Repco Home Finance rallies after Q4 PAT climbs 21% YoY
  15-May-24   14:52
  Speciality Restaurants Ltd leads losers in 'B' group
  15-May-24   14:45
  Volumes jump at ITI Ltd counter
  15-May-24   14:30
  FMCG shares fall
  15-May-24   14:00
  Banking stocks edge lower
  15-May-24   14:00
  Auto shares fall
  15-May-24   14:00
Back Top